Xilio Therapeutics Inc. (XLO) NASDAQ
$2.46 -0.06 (-2.38%)
Market Cap: $67.58M
As of 08/12/22 04:30 PM EDT. Market closed.
Xilio Therapeutics Inc. (XLO) NASDAQ
$2.46 -0.06 (-2.38%)
Market Cap: $67.58M
As of 08/12/22 04:30 PM EDT. Market closed.
Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. ... read more
Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly-owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15. read less
Open in:
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 08, 2021 | Buy | $9.62 | 13,458 | 129,474 | 2,776,402 | Dec 10, 2021, 08:33 PM |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 10, 2021 | Buy | $9.65 | 25,000 | 241,202 | 2,805,413 | Dec 10, 2021, 08:33 PM |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 09, 2021 | Buy | $9.84 | 4,011 | 39,485 | 2,780,413 | Dec 10, 2021, 08:33 PM |
| SV7 Impact Medicine Fund LP | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 312,500 | 5,000,000 | 1,613,632 | Nov 03, 2021, 04:20 PM |
| SV7 Impact Medicine Fund LP | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 312,500 | 5,000,000 | 1,613,632 | Nov 03, 2021, 04:20 PM |
| Flynn James E | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 387,500 | 6,200,000 | 1,143,972 | Oct 28, 2021, 07:15 PM |
| Flynn James E | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 387,500 | 6,200,000 | 1,143,972 | Oct 28, 2021, 07:15 PM |
| RiverVest Venture Fund IV, L.P. | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 250,000 | 4,000,000 | 1,441,444 | Oct 26, 2021, 05:30 PM |
| Rock Springs Capital Management LP | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 500,000 | 8,000,000 | 1,256,472 | Oct 26, 2021, 05:04 PM |
| BAY CITY CAPITAL LLC | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 312,500 | 5,000,000 | 1,129,490 | Oct 26, 2021, 05:02 PM |
| Atlas Venture Fund XI, L.P. | 10% Owner | Oct 26, 2021 | Buy | $16.00 | 187,500 | 3,000,000 | 735,942 | Oct 26, 2021, 05:01 PM |
| Owner | Relationship | Date | Value($) |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/08/2021 | 129,474 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/10/2021 | 241,202 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 12/09/2021 | 39,485 |
| SV7 Impact Medicine Fund LP | 10% Owner | 10/26/2021 | 5,000,000 |
| SV7 Impact Medicine Fund LP | 10% Owner | 10/26/2021 | 5,000,000 |
| Flynn James E | 10% Owner | 10/26/2021 | 6,200,000 |
| Flynn James E | 10% Owner | 10/26/2021 | 6,200,000 |
| RiverVest Venture Fund IV, L.P. | 10% Owner | 10/26/2021 | 4,000,000 |
| Rock Springs Capital Management LP | 10% Owner | 10/26/2021 | 8,000,000 |
| BAY CITY CAPITAL LLC | 10% Owner | 10/26/2021 | 5,000,000 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 10/26/2021 | 3,000,000 |
Period of Report: 06/30/2022
10-K/10-Q Filings: View